Aptima HBV Quant assay

HBV Treatment Management
in Sharp Focus

The Aptima HBV Quant assay quantifies HBV DNA and is intended for use as an aid in the clinical management of patients with chronic HBV infection.1

Contact a rep about the Aptima HIV-1 Quant Dx assay for the diagnosis of HIV-1

Quantitate With Confidence

The only molecular HBV treatment management assay to use a dual-target design. Accuracy in the face of high and low viral loads, genotype variation and mutations, so you can deliver trusted results from baseline measurement throughout treatment.

Unique design. Ultimate confidence.

The Aptima HBV Quant assay is the only dual-target molecular assay for HBV treatment monitoring.1

  • Targets 2 highly conserved regions in the polymerase and surface genes.
  • Provides added tolerance to mutations in the HBV genome.
  • Ensures accurate quantitation over a wide linear range.

Back to top

Dynamic range for a dynamic target.

With a wide linear range, the Aptima HBV Quant assay accurately quantifies HBV DNA as low as 10 IU/mL and as high as 1 billion IU/mL in plasma and serum samples, for reliable results even as viral load peaks and declines over the course of treatment.1

The linear range of the Aptima HBV Quant assay has been thoroughly validated across HBV genotypes A-H, for added confidence in your results.1

Back to top

Track even low-level concentrations of HBV virus, across all major HBV genotypes.

The Lower Limit of Quantitation (LLoQ) of the Aptima HBV Quant assay is 5.58 IU/mL in plasma samples and 6.34 IU/mL in serum samples, from only 500 μL of reaction volume.*

The LLoQ of the Aptima HBV Quant assay has been thoroughly and rigorously validated across HBV genotypes A-H with thousands of data points, across multiple reagent lots, instruments and operators.1

Back to top

Panther goes one step further.

With the Aptima HBV Quant assay, derive neat concentrations for pre-diluted samples on the fully automated Panther system:

  • Receive quantitative results for difficult samples, such as low-volume and high titer samples.
  • Reduce the risk of human error with automated calculation of neat value.

Back to top

Real-time TMA: Proprietary amplification technology from Hologic.

Learn how real-time TMA technology ensures accurate detection and quantitation of HBV DNA through highly specific and sensitive target capture.

Back to top

Ordering information


*Calculated using the WHO 3rd International Standard.


  1. Aptima HBV Quant Assay [package insert]. #AW-13182 Rev. 001. San Diego, CA; Hologic, Inc., 2015.